Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import from EEU countries to Russia (June 2018)

Monday, July 30, 2018

Between January and June 2018, Russia imported 5.9 bln RUB worth of pharmaceutical drugs produced in the EEU countries (wholesale prices, VAT included), which is in monetary terms more than 11% higher than that of the same period of 2017. In physical terms, Russia imported 99.7 mln units of drugs, which is 4.3% lower than that of the same period of 2017.

The import follows the current market tendencies: if calculated in minimum dosage units (MDU), the dynamics are +5%.

There has also been a change in the import line. Since January, Russia has imported 112 trademarks, including 12 new ones. In particular, the import of Ciprofloxacine (Kelun-Kazpharm) has risen by 191 times in monetary terms. Among the top 20 trademarks with the highest import in monetary terms are three products that were not imported in 2017. These are Docetaxel (Kelun-Kazpharm), Next Uno Express (Pharmstandard), and Cefepime (Farmgid.)

The absolute leader is still Belarus (+70%.) Pharmland and Pharmsynthez have the best dynamics, with a 25 and 9 times increase in monetary terms, respectively. Pharmsynthez imports only one product, which is anti-tumor drug Fludarabel. Kazakhstan follows with +29% , Kelun-Kazpharm has increased its import by nearly 8 times. Nobel-Ilac has the lowest dynamics, with -83%.

Volume and dynamics of pharmaceutical drug import from EEU countries to Russia (wholesale prices, VAT included) (2016 – June 2018)